Konstantinos Syrigos

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Bogdan Żurawski et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action

Konstantinos G. Kyriakoulis, Evangelos Dimakakos, Garyphallia Poulakou et al. · British Journal of Haematology · 2020 · 533 citations · Full text

Medicine, Hematology, Infectious Diseases +17

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Johan Vansteenkiste, Lucio Crinò, Christophe Dooms et al. · Annals of Oncology · 2014 · 495 citations · Full text

Medicine, Oncology, Surgery +16

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 434 citations

Medicine, Oncology, Pharmacology +9